학술논문
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Author
Platzbecker, U.; Santini, V.; Fenaux, P.; Sekeres, M.A.; Savona, M.R.; Madanat, Y.F.; Díez-Campelo, M.; Valcárcel, D.; Illmer, T.; Jonášová, A.; Bělohlávková, P.; Sherman, L.J.; Berry, T.; Dougherty, S.; Shah, S.; Xia, Q.; Sun, L.; Wan, Y.; Huang, F.; Ikin, A.; Navada, S.; Feller, F.; Komrokji, R.S.; Zeidan, A.M.
Source
In: The Lancet . (The Lancet, 20 January 2024, 403(10423):249-260)
Subject
Language
English
ISSN
1474547X
01406736
01406736